DOTATOC: a powerful new tool for receptor-mediated radionuclide therapy

Eur J Nucl Med. 1997 Jul;24(7):792-5. doi: 10.1007/BF00879669.


This study presents the first successful use of a peptidic vector, DOTATOC, labelled with the beta-emitting radioisotope yttrium-90, for the treatment of a patient with somatostatin receptor-positive abdominal metastases of a neuroendocrine carcinoma of unknown localization. Tumour response and symptomatic relief were achieved. In addition, the new substance DOTATOC was labelled with the diagnostic chemical analogue indium-111 and studied in three patients with histopathologically verified neuroendocrine abdominal tumours for its diagnostic sensitivity and compared with the commercially available OctreoScan. In all patients the kidney-to-tumour uptake ratio (in counts per pixel) was on average 1. 9-fold lower with 111In-DOTATOC than with OctreoScan. DOTATOC could be a potential new diagnostic and therapeutic agent in the management of neuroendocrine tumours.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abdominal Neoplasms / diagnostic imaging*
  • Abdominal Neoplasms / metabolism
  • Abdominal Neoplasms / radiotherapy*
  • Adult
  • Humans
  • Indium Radioisotopes*
  • Male
  • Middle Aged
  • Neuroendocrine Tumors / diagnostic imaging*
  • Neuroendocrine Tumors / metabolism
  • Neuroendocrine Tumors / radiotherapy*
  • Octreotide / analogs & derivatives*
  • Octreotide / therapeutic use
  • Pentetic Acid / analogs & derivatives
  • Radionuclide Imaging
  • Radiopharmaceuticals / therapeutic use*
  • Receptors, Somatostatin / analysis*
  • Sensitivity and Specificity
  • Yttrium Radioisotopes / therapeutic use*


  • Indium Radioisotopes
  • Radiopharmaceuticals
  • Receptors, Somatostatin
  • Yttrium Radioisotopes
  • SDZ 215-811
  • Pentetic Acid
  • Octreotide
  • Edotreotide